ArcherDX, Illumina expand cancer test partnership

By staff writers

January 10, 2020 -- Next-generation sequencing company ArcherDX has signed a comarketing deal with Illumina for its IVD cancer tests, including ArcherDX's lead product Stratafide, a pantumor companion diagnostic.

The deal will cover comarketing of ArcherDX tests for use with Illumina's NextSeq 550Dx and MiSeqDx systems. ArcherDX is developing a portfolio of genomic tests designed for guiding cancer treatment selection, monitoring response, and tracking outcomes over time.

The Stratafide test, which identifies actionable genomic alterations in blood or tissue samples, will be the first diagnostic marketed through the partnership, according to the companies. The assay has received the breakthrough device designation from the U.S. Food and Drug Administration (FDA).

The pair have been working together since 2016 on a number of projects, including the development of ArcherDX IVD tests for Illumina's NextSeq and MiSeq systems. In a statement about the expansion of the collaboration, ArcherDX noted that after Stratafide is approved by the FDA, it plans to file for approval of its personalized cancer monitoring (PCM) product, which is designed for the early detection of disease recurrence.

Illumina, PacBio $1.2B deal quashed
Illumina and Pacific Biosciences of California (PacBio) have terminated their merger plans in reflection of the lengthy regulatory approval process involved...
ArcherDX's $55M infusion bolsters Stratafide broad companion test
Molecular diagnostics company ArcherDX has closed a $55 million series C financing round and plans to use the cash to get its Stratafide companion...
ArcherDX partners with Illumina on companion tests
Diagnostics company ArcherDX is partnering with Illumina to develop its next-generation sequencing companion tests for oncology indications.
Lexent Bio partners on NGS with Illumina
San Francisco-based Lexent Bio has signed a nonexclusive deal to adapt its lead investigational Confera Dx next-generation sequencing (NGS) cancer test...
ArcherDX teams with Ayala on companion tests
ArcherDX plans to develop companion molecular diagnostic tissue and blood tests targeted at cancers with Notch-activating mutations and fusions, as part...

Copyright © 2020

Last Updated np 1/10/2020 12:58:09 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.